Objective: Vibration-controlled transient elastography (VCTE) is increasingly used to assess liver fibrosis in viral hepatitis and fatty liver disease populations. Because the accuracy of VCTE in HIV-monoinfected populations has not been established, we evaluated its performance in assessing liver fibrosis in a cohort of HIV-monoinfected adults undergoing liver biopsy as part of a recently published clinical trial.
Background
Aminotransferase elevations are common in HIVinfected adults receiving antiretroviral therapy (ART) and are associated with a high rate of liver disease, including nonalcoholic steatohepatitis (NASH) and fibrosis, in those without hepatitis B or C co-infection [1] . Noninvasive markers that can reliably determine the severity of underlying pathology can play an important role in the management of such patients. However, there is considerable overlap in clinical markers between those with and without significant liver pathology, and the performance of noninvasive markers has not been well established in this population [1] .
Liver biopsy -the gold standard for diagnosis and staging of NASH and fibrosis -has several limitations. Biopsy is invasive, has potentially serious complications [2] , and sampling errors can result in inaccurate estimates of the degree of liver damage [3, 4] . A noninvasive test or combination of tests that could reliably identify patients with fibrosis would allow targeting of liver biopsy to those most likely to benefit. This may be even more critical in the management of HIV-infected patients who have a high rate of nonalcoholic fatty liver disease (NAFLD) and in whom co-existing liver disease cannot be excluded without biopsy.
Vibration-controlled transient elastography (VCTE) has been shown to have good sensitivity and specificity for detection of advanced fibrosis in HIV and viral hepatitis co-infected patients [5] , as well as in HIV-negative NASH populations [6] . However, one limitation of VCTE is a high failure rate, usually in the setting of abdominal obesity and increased waist circumference [7] . Moreover, liver stiffness can vary with aminotransferase flares [8] and is unreliable in the setting of acute liver injury [9] . Despite these potential limitations and a lack of validation in HIVmonoinfected patients, clinical trials are increasingly using VCTE to study liver stiffness in HIV-infected populations [10, 11] .
To assess the accuracy of VCTE for the detection of fibrosis in HIV-moninfected adults, we performed VCTE in participants in a recently published study of HIVinfected adults with elevated aminotransferases and without chronic viral hepatitis who were undergoing liver biopsy.
Methods

Study population
The methods of the observational cross-sectional study have been published [1] . HIV-infected adults with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations greater than the upper limit of normal (AST >34 U/l or ALT > 41 U/l) on at least three occasions over at least 6 months while receiving combination ART for at least 1 year were eligible if they had no evidence of active viral hepatitis, hereditary or autoimmune liver disease, or hemochromatosis, no ongoing alcohol abuse, and no contraindication to liver biopsy.
The National Institute of Allergy and Infectious Diseases Institutional Review Board approved the protocol and all participants provided written informed consent.
Laboratory testing
Laboratory assessment prior to liver biopsy included complete blood counts, AST, ALT, alkaline phosphatase, gamma-glutamyl transpeptidase (GGT), bilirubin, and albumin. HIV viral load was measured by PCR (RealTime HIV-1 Assay; Abbott Laboratories, Des Plaines, Illinois, USA; lower limit of quantification 40 copies/ml) and CD4 þ T-cell counts by flow cytometry.
The AST/platelet ratio index (APRI) [12] , fibrosis-4 (FIB-4) [13] , and non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) [14] indices were calculated as noninvasive markers of fibrosis, using laboratory and clinical parameters at the time of study enrollment.
Transient elastography
Liver stiffness was determined using VCTE (FibroScan; Echosens, Paris, France) [15] . At least 10 measurements were made using the M-probe according to the manufacturer's recommendations, and the median, expressed in kilopascal (kPa) units, is determined [16] . Results were considered reliable if the success rate was at least 60% and the interquartile range/median ratio was 0.30 or less.
Liver histology
Percutaneous liver biopsy was performed under ultrasound guidance using an 18-gauge needle. One liver biopsy fragment was fixed in formalin. Paraffinembedded sections were stained with hematoxylin and eosin, Masson's trichrome, special stains for iron and copper, and for reticulin. Liver biopsies were read by a single liver pathologist (D.E.K.). Liver biopsies with less than 10 portal tracts were excluded from analysis.
Fibrosis and inflammatory activity were scored according to the modified histology activity index (Ishak) scoring system [17] . Steatosis was graded on a scale of 0-4 based on the percentage of cells with fat. Histological features of NAFLD were also scored according to the NASH Clinical Research Network (CRN) scoring system [18] .
Statistical analyses
The diagnostic performance of VCTE, APRI, FIB-4, and NAFLD-FS for the prediction of significant fibrosis (Ishak fibrosis score !2) was assessed by receiveroperating characteristic (ROC) curve methodology. Sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated using cut-off values established in other liver disease populations [12, 14, 19] . Multivariate analyses were not undertaken because the relatively small number of cases (14) precluded stable estimates and valid inferences. Comparisons of those with and without fibrosis ( Fig. 1) were made using the Wilcoxon rank-sum test with a Bonferroni adjustment for multiple comparisons.
Two-sided P values less than 0.05 were considered significant. Analyses were performed using GraphPad Prism (version 6.0; GraphPad Software, Inc., La Jolla, California, USA).
Results
Participants
Vibration-controlled transient elastography was performed on 58 of the previously reported 62 participants in the prospective biopsy cohort, as well as eight additional patients with a history of NASH on prior liver biopsy who enrolled in the natural history arm of the study for repeat liver biopsy and follow-up.
The characteristics of the 66 participants are shown in Table 1 . The cohort was in the majority male (92%), and the median age of participants was 50 years (range 17-68 years). Median duration of HIV infection at biopsy was 17 years (range 1-28 years). Median ALT was 79 IU/ml (range 27-1244 IU/ml); 16 (24%) had ALT elevations greater than three times the upper limit of normal (>123 IU/ml).
Liver biopsy identified bridging fibrosis in 14 (21%) and NASH in 38 (58%). Portal venopathy was identified in one participant and nodular regenerative hyperplasia (NRH) in two participants. Nonspecific changes, including mild-to-moderate steatosis and mild inflammation, were seen in 22 (33%) patients.
Vibration-controlled transient elastography
Vibration-controlled transient elastography was unsuccessful in three participants with obesity (all with NASH) and unreliable in an additional four participants (two with NASH, two with nonspecific changes on biopsy) -a failure rate of 11%. In the 59 participants with reliable results, median liver stiffness value was 5.9 kPa (range 3.3-29.2 kPa); 25 participants (42%) had score above 7.1 kPa -a value consistent with increased liver stiffness in other liver disease populations [6, 20] .
The sensitivity and specificity of VCTE for detection of moderate fibrosis was good, with an area under the ROC curve (AUROC) of 93% for F ! 2 [95% confidence interval (CI) 86-99%]. A prespecified cut-off for VCTE of 7.1 kPa gave a sensitivity of 93% and a specificity of 73% for F ! 2 ( Table 2 ). The NPV to exclude F ! 2 was 97%. The liver stiffness cut-off that optimized performance in our cohort -7.2 kPa -was similar to the prespecified Ishak fibrosis score
Ishak or NASH CRN fibrosis score cut-off of 7.1 kPa, with a sensitivity of 93% and a specificity of 75% for detection of F ! 2.
The sensitivity and specificity of VCTE for the detection of any fibrosis was also good with AUROC of 89% (95% CI 78-97%) for Ishak F > 0 and/or NASH CRN F > 0. A prespecified cut-off for VCTE of 7.1 kPa gave a lower sensitivity of 75% and a better specificity of 96%. The NPV to exclude any fibrosis was 76%; PPV to detect any fibrosis was 96%.
In an 'intention-to-treat' analysis, all patients who underwent VCTE and liver biopsy were analyzed (n ¼ 66). Participants with unreliable results were categorized based on the reported liver stiffness value, and those with unsuccessful VCTE were considered as not correctly classified. At the cut-off of 7.1 kPa, the NPV of VCTE in detecting F ! 2 remained high at 97%. However, PPV declined slightly to 46%.
Liver stiffness was elevated (>7.1 kPa) in 21/33 (64%) participants with steatohepatitis, all with at least some fibrosis on biopsy (Ishak F > 0 or NASH CRN F > 0). One participant with advanced fibrosis (Ishak F4), not associated with NASH, had a VCTE of 6.9 kPa. VCTE was greater than 7.1 kPa in both participants with NRH.
Comparison with noninvasive laboratory markers of fibrosis
The performance of VCTE, APRI, FIB-4, and NAFLD-FS for the detection of significant fibrosis is presented in Table 2 . VCTE had the best diagnostic performance. Unlike the other predictors, VCTE had high values for both sensitivity and specificity, and had a very high AUROC (Fig. 2 ).
Discussion
Vibration-controlled transient elastography was the best noninvasive predictor of fibrosis in this cohort of HIV-monoinfected adults, with a high sensitivity and a good specificity for detecting moderate-to-severe fibrosis in a population in which the most prevalent liver disease was NASH.
Our results mirror those seen in HIV-negative NAFLD patients. In one study of 246 adults with NAFLD, the AUROC for significant fibrosis was 0.93 [6] . At a liver stiffness cut-off of 7.9 kPa, the sensitivity, specificity, and PPVand NPV for significant fibrosis were 91, 75, 52, and 97%, respectively. A failure rate of 13% was described. Similar performance is seen in studies of VCTE in HCVmonoinfected and HIV/HCV-co-infected cohorts, with mean AUROC for the diagnosis of significant fibrosis of 0.84 [5, 20, 21] .
The noninvasive biomarkers APRI, FIB4, and NAFLD-FS performed poorly, with sensitivities ranging from 14 to 21%. The performance of these biomarkers can vary with disease state [22] . APRI, for example, performs best in hepatitis C-monoinfected cohorts and may be less useful in the setting of HIV-related thrombocytopenia. Further, APRI performs poorly in studies of NASH in 2300 AIDS 2015, Vol 29 No 17 HIV-negative populations [6] . While potentially useful for the identification of advanced liver disease in certain settings, these markers failed to identify significant fibrosis in the current study of HIV monoinfection and elevated aminotransferases, and should be used cautiously in screening studies of HIV-monoinfected patients.
Our study was conducted only in HIV-infected adults with suppressed HIV viremia on ART, and these results should be extended cautiously to untreated HIV-infected populations in which HIV may directly promote hepatic inflammation and damage. Other limitations of our study include the small size of the study population and conduct at a referral center where the population is likely enriched for liver disease and fibrosis. However, VCTE can exclude severe fibrosis, with a specificity above 70% in these patients, even in the setting of an 11% failure rate. Using the same cut-off (7.1 kPa), the specificity for any fibrosis (Ishak F > 0) is 97%, potentially ruling out a need for further evaluation in patients with results below this value. The failure rate, similar to that seen in other similar studies, may be reduced in the future given the availability of an XL probe for use with obese patients. This probe was not available at our institution at the time of this study.
In a cohort of HIV-infected adults with biopsy-proven liver disease, liver stiffness measured by VCTE was the best noninvasive predictor of fibrosis. With an excellent NPV and good PPV, VCTE is a useful screening test to exclude advanced fibrosis in HIV-monoinfected patients with elevated aminotransferases. Staging of liver fibrosis is critical to the prognosis and management of liver disease in HIV-infected patients, and VCTE can help identify those most likely to require liver biopsy for definitive diagnosis and targeted management.
